Introduction {#Sec1}
============

Phosphine (PH~3~) has been widely used as an insecticide for grain reserves since the 1930s. Due to various advantages, including its low cost, high toxicity, minimal residue, and rapid action, PH~3~ has replaced the ozone-harming chemical methyl bromide as the most popular fumigant worldwide^[@CR1]^. However, with prolonged use of PH~3~, pests with high levels of resistance have been reported in many countries, such as the United States, Australia, and Brazil^[@CR2]--[@CR4]^. As there is no effective chemical replacement for PH~3~, much effort has been devoted to studying the mechanisms of PH~3~ toxicity and resistance^[@CR5]^.

To date, the precise mode of PH~3~ toxicity is still unclear. One of the mechanisms involved is the generation of reactive oxygen species (ROS)^[@CR6]^. ROS can lead to oxidative stress, lipid peroxidation, and toxic changes to the redox state of the cell, leading to a failure of oxidative respiration^[@CR7]--[@CR10]^. In support of this, antioxidants such as glutathione and melatonin can prevent most of the oxidative damage induced by PH~3~ ^[@CR11],[@CR12]^.

PH~3~ can also disrupt the antioxidant defence system^[@CR13]^. Typically, high levels of ROS will activate the antioxidant defence system of the cell^[@CR14]^, inducing the up-regulation of various antioxidant enzymes such as superoxide dismutase (SOD) and catalase (CAT). However, while SOD is up-regulated after PH~3~ treatment, expression and activity of CAT, which can decompose hydrogen peroxide to water and oxygen, are inhibited by PH~3~ ^[@CR15],[@CR16]^. It was proposed that PH~3~ may inhibit CAT by reducing the metal ion cofactor in the active site^[@CR17]^. However, the inhibitory effect could only be observed *in vivo* but not *in vitro*, suggesting that there may be other regulatory mechanisms^[@CR16],[@CR18]^. Previously, we found that PH~3~ fumigation could reduce mRNA production of the *DmCAT* gene in *Drosophila melanogaster*, which was the first evidence that PH~3~ may disrupt the antioxidant defence system at transcriptional level, adding another layer of complexity to the function of PH~3~ ^[@CR19]^. However, the mechanism by which PH~3~ inhibits *DmCAT* transcription is unknown.

In the current study, we investigated whether PH~3~ could directly regulate the transcription of *DmCAT* by dissecting the role of the *DmCAT* promoter in PH~3~-mediated *DmCAT* inhibition in *D*. *melanogaster* S2 cells. We first established a PH~3~ treatment system using S2 cells and confirmed that it led to down-regulation of *DmCAT*. We then developed a luciferase reporter assay and identified an essential fragment containing a DNA replication-related element (DRE) within the *DmCAT* promoter. This element was sufficient and necessary for PH~3~-mediated *DmCAT* repression. We then showed that levels of DREF, the DRE-binding transcription factor, were reduced upon PH~3~ treatment and that this phenomenon was an essential prerequisite for *DmCAT* repression. These data suggest that PH~3~ inhibits *DmCAT* promoter activity by reducing levels of the transcription factor DREF, providing a new mechanism for the mode of action of PH~3~.

Results {#Sec2}
=======

PH~3~ treatment reduces the expression of *DmCAT* in *D*. *melanogaster* S2 cells {#Sec3}
---------------------------------------------------------------------------------

To gain insight into the molecular mechanism of PH~3~-mediated *CAT* gene repression, we established a PH~3~ treatment system in *D*. *melanogaster* S2 cells. We observed that PH~3~ treatment inhibited the growth of S2 cells, with clear dose and time dependencies (Fig. [1A](#Fig1){ref-type="fig"}). At a concentration of 14 µg/L and a treatment time of 48 h, PH~3~ led to the death of 40% of cells.Figure 1Establishment of phosphine (PH~3~) treatment system in *Drosophila melanogaster* S2 cells. (**A**) Cell viability assays for S2 cells treated with different concentrations of PH~3~ for various lengths of time. (**B**) Real-time PCR analysis of the *DmCAT* gene in S2 cells treated with 14 µg/L PH~3~ for 0, 1, 2, or 4 h. CK: control. Lowercase letters indicate significant differences at p \< 0.05. (**C**) Western blot against DmCAT in S2 cells treated with 14 µg/L PH~3~ for 0, 1, 2, or 4 h (Full-length blots are presented in Supplementary Figs [S1](#MOESM1){ref-type="media"} and [S2](#MOESM1){ref-type="media"}).

To examine the expression of the *DmCAT* gene, we performed reverse transcription real-time PCR and western blotting after treating S2 cells with 14 µg/L PH~3~ for 1, 2, and 4 h. We observed a considerable decrease in *DmCAT* at both mRNA and protein level (Fig. [1B,C](#Fig1){ref-type="fig"}). These data indicated that this system could faithfully recapitulate PH~3~-mediated growth inhibition and *CAT* gene repression^[@CR19]^.

A DRE consensus motif within the *DmCAT* promoter is required for PH~3~-mediated transcription inhibition {#Sec4}
---------------------------------------------------------------------------------------------------------

To directly investigate the role of the *DmCAT* promoter in PH~3~-mediated *DmCAT* repression, we cloned the full-length (−1,944 to 0 bp)^[@CR20]^ and various truncated fragments of the *DmCAT* promoter into the pGL4.11 \[luc2P\] luciferase reporter vector. PH~3~ treatment reduced luciferase activity to 32.9% when the full-length *DmCAT* promoter was used, indicating that the promoter was directly involved in PH~3~-mediated *DmCAT* repression (Fig. [2A](#Fig2){ref-type="fig"}). However, four truncated promoter fragments showed similar efficacy in reducing luciferase activity upon PH~3~ treatment (Fig. [2B](#Fig2){ref-type="fig"}), suggesting that the core response unit lay within the −94 to 0 bp region.Figure 2A minimal fragment containing a DNA replication-related element (DRE) motif is required for phosphine (PH~3~)-mediated *DmCAT* repression. (**A**) Promoter activity of wild-type (−1,944 full length and −94) and mutant (−94 M) DRE *DmCAT* promoters treated with or without PH~3~. (**B**) Luciferase assay comparing PH~3~ inhibition efficiencies of full-length (−1,944) and various truncated fragments of *DmCAT* promoter. Relative promoter activity was defined as the ratio of luciferase activity in PH~3~-treated cells to that in untreated cells. DRE-WT, wild-type DRE; DRE-M, mutant DRE. Lowercase letters indicate significant differences at p \< 0.05.

It was previously reported that a DRE element was present in the *DmCAT* promoter at positions −78 to −85 bp^[@CR20]^. This element, together with its binding protein, DREF, is required for the positive regulation of *DmCAT* during fruit fly development^[@CR20]^. To investigate whether this DRE element was required for PH~3~-mediated *DmCAT* repression, we mutated three critical nucleotides within the DRE consensus sequence and assessed the mutant promoter with the luciferase assay. Consistent with a positive role of DRE in *DmCAT* regulation, DRE mutations strongly reduced promoter activity (by 99%) in S2 cells without PH~3~ treatment (Fig. [2A](#Fig2){ref-type="fig"}). Interestingly, after treatment with PH~3~, relative luciferase activity was reduced by only 16.5% when using the DRE mutant promoter rather than by 61.7%, as observed for the full-length promoter (Fig. [2A,B](#Fig2){ref-type="fig"} and Supplementary Table [S1](#MOESM1){ref-type="media"}). These data suggested that DRE was critical for PH~3~-mediated *DmCAT* repression.

PH~3~ reduces the activity of the *DmCAT* promoter through inhibition of *DREF* expression {#Sec5}
------------------------------------------------------------------------------------------

Previously, we found that PH~3~ treatment led to reduced DREF levels in the fruit fly^[@CR19]^. We observed similar effects in S2 cells at both protein and mRNA level (Fig. [3A,B](#Fig3){ref-type="fig"}). Additionally, a Chip-qPCR analysis was performed to compare the occupancy of Pol II on the *DREF* promoter with or without PH~3~ treatment. Our results showed that Pol II occupancy was greatly reduced upon PH~3~ treatment, suggesting that transcription activity could directly contribute to reduced *DREF* mRNA abundance (Fig. [3C](#Fig3){ref-type="fig"}). These data provided a possible explanation for PH~3~-mediated *DmCAT* repression, with PH~3~ down-regulating the expression of *DREF* at transcriptional level, and low amounts of DREF resulting in reduced *DmCAT* promoter activity.Figure 3Repression of DREF by phosphine (PH~3~). (**A**) Western blot (Full-length blots are presented in Supplementary Figs [S3](#MOESM1){ref-type="media"} and [S4](#MOESM1){ref-type="media"}) and (**B**) real-time PCR analysis of *DREF* in S2 cells treated with 14 µg/L PH~3~ for 0, 1, 2, or 4 h. CK: control. (**C**) Chromatin immunoprecipitation (ChIP)-qPCR analysis of Pol II enrichment on the *DREF* promoter with or without PH~3~ treatment. Lowercase letters indicate significant differences at p \< 0.05. TSS, transcription start site.

To test this hypothesis, we performed the luciferase assay under *DREF* knockdown or overexpression conditions. In both cases, we would expect luciferase activity not to respond to PH~3~ treatment, since there would be either no DREF or constitutively high levels of DREF, respectively. Double-stranded RNA-mediated *DREF* knockdown efficiently depleted DREF protein levels (Fig. [4A](#Fig4){ref-type="fig"}). Consistent with the positive role of the DRE/DREF system in *DmCAT* regulation, we observed reduced luciferase activity after *DREF* knockdown (Fig. [4B](#Fig4){ref-type="fig"}). After PH~3~ treatment, we observed a dramatic decrease in luciferase activity in mock knockdown cells but not in *DREF* knockdown cells, suggesting that DREF is essential for PH~3~-mediated *DmCAT* repression (Fig. [4B](#Fig4){ref-type="fig"}).Figure 4Effect of *DREF* RNAi and overexpression on phosphine (PH~3~)-mediated *DmCAT* repression. (**A**) Representative western blot validating the efficiency of *DREF* RNAi. CK: control (Full-length blots are presented in Supplementary Figs [S4](#MOESM1){ref-type="media"} and [S5](#MOESM1){ref-type="media"}). (**B**) Luciferase assay comparing relative luciferase activities of control and *DREF* RNAi cells with or without PH~3~ treatment. \*p \< 0.05 vs. untreated cells. (**C**) Representative western blot validating the overexpression of DREF (Full-length blots are presented in Supplementary Figs [S4](#MOESM1){ref-type="media"} and [S6](#MOESM1){ref-type="media"}). (**D**) Luciferase assay comparing relative luciferase activities of control or DREF overexpressing cells with or without PH~3~ treatment. \*p \< 0.05 vs. untreated cells.

For DREF overexpression, we cloned the full-length *DREF* open reading frame into the pAc5.1/V5-His expression vector and transfected this vector along with the pGL4.11-pCAT \[luc2P\] luciferase reporter. Western blot confirmed the overexpression of DREF protein (Fig. [4C](#Fig4){ref-type="fig"}). We observed higher luciferase activity in *DREF* overexpressing cells, again supporting its positive role in *DmCAT* expression. After PH~3~ treatment, we found that luciferase activity was reduced only in control transfected cells and not in *DREF* overexpressing cells, further supporting our hypothesis (Fig. [4D](#Fig4){ref-type="fig"}).

Effect of PH~3~ on the expression of DREF target genes {#Sec6}
------------------------------------------------------

As recently reviewed by Nguyen *et al*., DREF is a multifunctional factor, and could positively regulate the expression of genes other than *CAT* ^[@CR21]^. To determine whether these DREF target genes were also targets of PH~3~, we investigated the expression of seven DREF target genes including *WARTS* ^[@CR22]^, *TTF* ^[@CR23]^, *TFB2* ^[@CR24]^, *HIPPO* ^[@CR25]^, *OSA* ^[@CR26]^, *MOIRA* ^[@CR26]^, and *P53* ^[@CR27]^ in S2 cells after PH~3~ treatment. Our results showed that the expression of *TTF* and *TFB2*, which are related to mitochondrial function, were partly reduced after PH~3~ treatment, indicating that the DRE/DREF system might play a common role in relaying the PH~3~ signal to its target genes (Fig. [5](#Fig5){ref-type="fig"}).Figure 5Effect of phosphine (PH~3~) on the expression of seven DREF target genes. \*p \< 0.05 vs. untreated cells.

Discussion and Conclusion {#Sec7}
=========================

This and our most recent studies demonstrate that PH~3~ inhibits catalase activity via transcriptional regulation^[@CR19]^. Previous studies mostly focused on the direct inhibition of catalase enzymatic activity by PH~3~ ^[@CR15],[@CR16]^. While these two mechanisms are not necessarily mutually exclusive, it should be noted that the enzymatic inhibition of catalase could only be observed *in vivo* but not *in vitro*, suggesting that enzymatic regulation might not be direct^[@CR16],[@CR18]^. In addition, reduction of the metal ion cofactor of catalase by PH~3~ could not explain why PH~3~ has the opposite effect on superoxide dismutase, which also has metal cofactors.

The observation that PH~3~ treatment results in down-regulation of *DmCAT* mRNA in *D*. *melanogaster* led us to investigate how PH~3~ affected *DmCAT* transcription at the molecular level. By devising a luciferase reporter system in *D*. *melanogaster* S2 cells, we demonstrated that *DmCAT* promoter activity was strongly repressed upon PH~3~ treatment. This response was quick (within 1 h), indicating that it may not be a downstream effect of antioxidant system failure. Further dissection of the *DmCAT* promoter showed that a small fragment (−94 to 0 bp) was necessary and sufficient for PH~3~ responsiveness (Fig. [2](#Fig2){ref-type="fig"}). Interestingly, we found that a DRE motif (−78 to −85 bp) was involved in this process. The *DmCAT* promoter with a mutated DRE sequence no longer responded to PH~3~ treatment, although basal promoter activity was greatly reduced. It has been reported that the *CAT* gene is positively regulated by the DRE/DREF system in *D*. *melanogaster* ^[@CR20]^, which raises an interesting question as to why a positive regulatory element would be involved in the negative regulation of the *CAT* gene.

The finding that levels of the positive regulatory factor DREF decrease after PH~3~ treatment provides a reasonable explanation for this discrepancy. PH~3~ treatment does not directly inhibit the *DmCAT* promoter, but rather it reduces levels of the positive regulatory factor DREF. By manipulating levels of DREF via RNAi or overexpression experiments, we report that (1) the DREF level positively correlates with *DmCAT* promoter activity, consistent with a previous study^[@CR20]^; and (2) either depleting or overexpressing *DREF* renders the *DmCAT* promoter nonresponsive to PH~3~ treatment, suggesting that DREF is the critical factor for PH~3~-mediated *DmCAT* repression. Thus, the down-regulation of DREF by PH~3~ treatment is a prerequisite for repression of *DmCAT*.

DRE and the DRE-binding factor DREF are recognised as a multifunctional system with important roles in *D*. *melanogaster*, including tumour suppression, cell development, tissue growth, chromatin organisation, and mitochondrial biogenesis^[@CR21]^. Therefore, it is interesting to know whether other DRE/DREF target genes are also down-regulated by PH~3~ and, if so, what are their roles in PH~3~ toxicity. Our results showed that two DREF target genes related to mitochondrial function were down-regulated after PH~3~ treatment (Fig. [5](#Fig5){ref-type="fig"}). Considering that PH~3~ could also disrupt mitochondrial function and inhibit respiration in invertebrate organisms^[@CR6]^, it is possible that the DRE/DREF system is also involved in this process and is essential for relaying the PH~3~ signal to its targets genes. This will require comprehensive analysis of transcriptional changes upon PH~3~ treatment. Additional questions, which will be explored in future studies, include the exact down-regulation of DREF by PH~3~.

Investigations into how PH~3~ disrupts the antioxidant defence system and leads to the generation of ROS have produced important results in the field, especially in the context of emerging PH~3~ resistance. First reported more than two decades ago, PH~3~ resistance has now been observed in many countries. It may become a worldwide problem in the future, considering its predominant use and the consequent likelihood of imposing strong selection for PH~3~ resistance in pests. Studies on the molecular mechanism of PH~3~ toxicity will provide information to help address PH~3~ resistance, ultimately benefitting industries that rely on pest control.

Materials and Methods {#Sec8}
=====================

Preparation of the PH~3~ solution {#Sec9}
---------------------------------

Gaseous PH~3~ was generated by adding aluminium phosphide tablets to acidified water^[@CR28]^. To make the PH~3~ solution, PH~3~ gas (1 mL) was injected into a sealed, sterile Wheaton narrow-mouth bottle (Z250007; Sigma, St. Louis, MO, USA) containing 1 × PBS, pH 7.4 (15 mL), through a Mininert Valve (33304; Sigma). The bottle was inverted overnight at 28 °C to allow it to equilibrate. The concentration of the PH~3~ solution was determined to be 14 µg/mL using a QuantiChrom Phosphate Assay Kit (BioAssay Systems, Hayward, CA, USA) according to the manufacturer's protocol.

S2 cell culture and PH~3~ treatment procedures {#Sec10}
----------------------------------------------

*D*. *melanogaster* S2 cells were cultured in TC100 medium supplemented with heat-inactivated FBS (10%) and antibiotics at 28 °C. For cell viability assays, the cells were seeded into a 96-well plate at a density of 0.5 × 10^5^ per well. After 24 h, the medium was changed to fresh medium, and cells were treated with PH~3~ at a concentration of 1.4, 7, or 14 µg/L for 0, 12, 24, or 48 h. At each time point and for each treatment concentration, cell viability was evaluated using the CellTiter 96^®^ AQ~ueous~ One Solution Cell Proliferation Assay System (Promega, Madison, WI, USA)^[@CR29]^.

For real-time PCR and western blot assays, S2 cells were seeded into a 6-well plate at a density of 5 × 10^5^ per well. Cells were treated with PH~3~ at a concentration of 14 µg/L for 1, 2, or 4 h, and then were harvested for RNA and protein extraction.

Luciferase reporter construction and luciferase assay {#Sec11}
-----------------------------------------------------

There is only one identified gene encoding for CAT in *D*. *melanogaster*. The full-length promoter of *DmCAT* (−1,944 to 0 bp, relative to the transcriptional start site of *DmCAT*) was amplified with the following two primers: Full-Pcat-S-*XhoI*, 5′-CTCGAGACCTGGGTTTATGGGCTAA-3′; Full-Pcat-A-*BglII*, 5′-AGATCTGTAGTCAATCAACTGATTGGA-3′^[@CR20]^. Differently truncated fragments of the *DmCAT* promoter were amplified with the forward primers shown in Table [1](#Tab1){ref-type="table"}, and Full-Pcat-A-*BglII* was used as the reverse primer. To mutate the DRE sequence, which corresponds to positions −85 to −78 bp, the forward primer −94M-Pcat-S-*XhoI*, carrying three nucleotide mutations, was used.Table 1Primers for luciferase reporter construction.Primer nameSequence 5′--3′−1,449-Pcat-S-*XhoI*CTCGAGCAATTGGCTTCATGTTTCGTTTTCTTG−950-Pcat-S-*XhoI*CTCGAGAGTCAAGATTCAGACAATGTGCCTAC−229-Pcat-S-*XhoI*CTCGAGATCTTAATGGTGTTGGGACA−94-Pcat-S-*XhoI*CTCGAGTAATCGAAATATCGATATCTTCGGC−94M-Pcat-S-*XhoI*CTCGAGTAATCGAAATtagGATATCTTCGGC^11^Mutant nucleotides are denoted in lowercase.

The amplified fragments were cloned into the pGL4.11 \[luc2P\] vector with *XhoI* and *BglII*, resulting in pGL4.11-pCAT \[luc2P\]. This reporter, together with the control vector pGL4.74 \[hRluc/TK\], was co-transfected into S2 cells for 48 h^[@CR30]^. S2 cells were then treated with PH~3~ for another 4 h, followed by detection of luciferase activity with the Dual-Luciferase Reporter Assay System (Promega).

Real-time PCR {#Sec12}
-------------

Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Contaminating genomic DNA was removed using DNase I (Takara, Kusatsu, Japan). RNA (2 µg) was reverse transcribed using M-MLV Reverse Transcriptase (Promega). Real-time PCR was carried out with SYBR Green Real-time PCR master mix (Toyobo, Osaka, Japan). *RP49* was used as an endogenous control. The primers used are listed in Table [2](#Tab2){ref-type="table"}.Table 2Primers for real-time PCR.Gene namePrimer sequence 5′--3′*CAT* (CG6871)CCAAGGGAGCTGGTGCTTACGCCATCCTCAGTGTAGAA*DREF* (CG5838)GAAGCGGACCATTTCCAG*WARTS* (CG12072)GTTAGTGTGCGGAGCATTTCGCCGTCATCATCTTTGGCACA*TTF* (CG18124)ACTCAAGTCAATGGACTTTATCTCAGAGTTCAGAGCACCCA*TFB2* (CG3910)TTCGGCGCCGTGGGCTCCTATCTGTATATGGGTGGGGCATG*HIPPO* (CG11228)CCTCTTCGGCAGCATCTCCCGAATCGGAGTTGATTACCATA*OSA* (CG7467)CCCTGTCCCTGTCTTCTCACGATGGAACACCGGTAACCAC*MOIRA* (CG18740)CGACAAGGACGATGAAGAGGCGCTGATGATGATGTGGAAC*P53* (CG33336)CGCCCAAGTCTCTTTGGATGTACTCGCTTGAAGGCCAGGGTCTGGCGCGTG*RP49* (CG7939)CGATATGCCAAGCTAAAGCAGGGCGATCTCAGCACAGTAT

Western blot {#Sec13}
------------

Cells (10^6^) were harvested, and total protein was extracted with 200 µL lysis buffer (20 mM Tris-HCl pH 8.0, 2 mM MgCl~2~, 0.2 M sucrose). Then, protein (20 µg) was resolved by 13% SDS-PAGE and transferred to a PVDF membrane (Millipore, Billerica, MA, USA) using wet electro-transfer. CAT, DREF, and endogenous control β-actin were blotted with corresponding antibodies^[@CR26],[@CR27]^.

ChIP-qPCR {#Sec14}
---------

Chromatin immunoprecipitation (ChIP) was performed using the iDeal ChIP-seq kit (Diagenode, Denville, NJ, USA) according to the manufacturer's instruction with minor modifications. Briefly, 2 × 10^6^ PH~3~-treated or untreated cells were harvested in PBS and cross-linked with formaldehyde (1%) for 2 min. After sonication, chromatin from 1 × 10^6^ cells was subjected to ChIP with Pol II antibody (ab5408; Abcam, Cambridge, MA, USA). For ChIP-qPCR assays, four pairs of primers were used to amplify fragments at different distances downstream from the *DREF* transcription start site (TSS) (Table [3](#Tab3){ref-type="table"}). Pol II enrichment was normalised to the constitutively active glyceraldehyde-3-phosphate dehydrogenase promoter region using the *Drosophila* Positive Control Primer Set Gapdh1 (Active Motif, Carlsbad, CA, USA).Table 3Primers for chromatin immunoprecipitation (ChIP)-qPCR.Primer nameSequence 5′--3′DREF-0-ChIP-SCAAACAAGAAGATCCCAATCDREF-0-ChIP-RTCCAAAGTAGCGCCAGTADREF-250-ChIP-SCATCTCCAGCACCGACACDREF-250-ChIP-RAATGAACTCCAGTTTGACCCDREF-500-ChIP-SAACCACGATAACGCTTCCGDREF-500-ChIP-RCGCTCCTCCTCCTCTACCADREF-1000-ChIP-SCGCTTCCTTAGCATCTTCDREF-1000-ChIP-RCCTCTTCCTCGTCGTAGTT

RNAi in S2 cells {#Sec15}
----------------

RNAi was performed according to methods described by Fernández-Moreno *et al*. and Sawado *et al*.^[@CR23],[@CR31]^. To make double-stranded RNAs, plasmid templates containing the corresponding target sequences were first constructed. For DREF, a fragment ranging from nucleotide positions 720--1,321 flanked by T7 promoter sequences at both ends was ligated into pUC19. For mock RNAi, a LacZ sequence, a fragment ranging from nucleotide positions 2,528--348 of the pUC19 vector, flanked by T7 promoters was ligated to pUC19. These templates were *in vitro*-transcribed using the MEGAscript® RNAi kit (Ambion, Austin, TX, USA) according to the manufacturer's protocol. Next, *in vitro*-transcribed dsRNA (100 µg) was purified. For dsRNA treatment, 1.5 µg of dsRNA per 10^5^ S2 cells was directly added to unsupplemented TC100 medium. After 1 h of incubation, medium was changed to complete medium. After 24 h, the cells were transfected with luciferase reporters; 48 h later, cells were collected for real-time PCR, western blot, or luciferase activity assays.

Transient gene overexpression in S2 cells {#Sec16}
-----------------------------------------

The full open reading frame of the *D*. *melanogaster DREF* gene (NM_078805.4) was synthesised by Beijing Protein Innovation (Beijing, China) and ligated into the pAc5.1/V5-His vector with *Xho*I and *Xba*I. The expression vector was then transfected into S2 cells together with the luciferase reporter for 48 h. The transfected cells were then treated with PH~3~ for another 4 h, followed by real-time PCR, western blot, or luciferase activity assays.

Statistical analysis {#Sec17}
--------------------

All data were generated from at least three independent replicate experiments and processed with Microsoft Excel (Microsoft Corporation, Redmond, WA, USA). Final data are expressed as means ± SE. One-way ANOVA and LSD test were used to test for statistically significant differences at p \< 0.05.

Data availability {#Sec18}
-----------------

All data generated or analysed during this study are included in this published article.
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